Candel Therapeutics strengthens balance sheet as lead cancer therapy advances

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while reporting its fourth quarter and full-year 2025 financial results. “During the quarter, we made meaningful progress across our clinical pipeline and pre-commercial readiness, entering 2026 with strong momentum and a robust set of potential value-driving catalysts,” Candel CEO Paul Peter Tak said in a statement.